½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting




»¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

021-54845833/15800441009

Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > Ò»¿¹ > Íÿ¹ALK¶à¿Ë¡¿¹Ìå

²úÆ·ÖÐÐÄ

×îвúÆ·

  • Íÿ¹ALK¶à¿Ë¡¿¹Ìå

    ¹æ¸ñ£º
    ¼Û¸ñ£º£¤
    • Æ·ÅÆ : ͨεÉúÎï
    • Ŀ¼ºÅ : TW1754
    • Ó¦Óà : ½öÓÃÓÚ¿ÆÑÐʹÓÃ
    • »õÆÚ : ÏÖ»õ
    • ¹æ¸ñ £º100ul/200ul/25ul
  • ÉÌÆ·ÏêÇé
  • ²Î¿¼ÎÄÏ×
  • ˵Ã÷ÊéÏÂÔØ
  • ÉÌÆ·ÆÀÂÛ0
  • Ïà¹Ø²úÆ·

ÖÐÎÄÃû³Æ: Íÿ¹ALK¶à¿Ë¡¿¹Ìå

Ó¢ÎÄÃû³Æ:
Anti-ALK rabbit polyclonal antibody

±ð        Ãû: CD246; NBLST3

¿¹        Ô­:
ALK

´¢        ´æ:
Àä¶³£¨-20¡æ£©

ËÞ        Ö÷: Rabbit

·´Ó¦ÖÖÊô: Human

Ïà¹ØÀà±ð: Ò»¿¹

±ê ¼Ç Îï: Unconjugate

¿Ë¡ÀàÐÍ: rabbit polyclonal

¼¼Êõ¹æ¸ñ

Background:

This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).

Applications:

ELISA, IHC

Name of antibody:

ALK

Immunogen:

Synthetic peptide of human ALK

Full name:

anaplastic lymphoma receptor tyrosine kinase

Synonyms:

CD246; NBLST3

SwissProt:

Q9UM73

ELISA Recommended dilution:

5000-10000

IHC positive control:

Human liver cancer and human thyroid cancer

IHC Recommend dilution:

25-100




¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿